Skip to content
Review

Abstract 18663: Comparative Effectiveness and Safety of Myval versus Contemporary Transcatheter Aortic Valves: A Systematic Review and Network Meta-Analysis

Nov 2026 · Circulation · 0 citations

Abstract

Background: Transcatheter aortic valve implantation (TAVI) has become an established alternative to surgical aortic valve replacement for patients with symptomatic severe aortic stenosis. Myval has shown favourable outcomes; however, comparative evidence against established THVs remains limited. Hypothesis: We evaluated the comparative effectiveness and safety of Myval versus contemporary THVs in severe aortic stenosis. Methods: PubMed, Embase, Scopus, Cochrane, and ClinicalTrials.gov were searched through March 2026 for studies comparing Myval with contemporary THVs. Random-effects network meta-analysis was performed. Primary outcomes included PPI, 30-day mortality, stroke, major bleeding, and major vascular complications. Secondary outcomes included technical success, transvalvular aortic regurgitation, mean aortic valve gradient, and 1-year mortality. Risk of bias was assessed using RoB 2 and NOS, and certainty of evidence using CINeMA. Pooled RRs or MDs with 95% CIs were calculated. Results: Twelve studies (2 RCTs and 10 observational studies) comprising 5,444 patients across six THV platforms were included. Compared with Myval, Portico (RR 2.59, 95% CI 1.52-4.42, P-score =0.05) and Allegra (RR 1.99, 95% CI 1.08-3.69, P-score=0.22) were associated with significantly higher PPI rates, while Evolut showed a borderline increase (RR 1.62, 95% CI 0.99-2.66, P-score=0.36). No significant differences were observed between Myval and Sapien or Acurate valves for PPI. 30-day mortality, stroke, major bleeding, and major vascular complications were largely comparable across valves. Evolut showed higher transvalvular aortic regurgitation compared with Myval (RR 2.52, 95% CI 1.35-4.71, P-score=0.01). Technical success was lower with Evolut compared to Myval, whereas Sapien exhibited comparable technical success. For haemodynamics, Allegra (MD –2.26 mmHg, 95% CI –3.10 to –1.42, P-score=1.00) and Evolut (MD –1.37 mmHg, 95% CI –1.99 to –0.75, P-score=0.79) showed significantly lower mean aortic valve gradients than Myval, whereas Sapien had higher gradients (MD +2.70 mmHg, 95% CI +1.90 to +3.50, P-score=0.00). Mortality at 1-year did not differ significantly among valves. No significant publication bias or network inconsistency was detected; overall confidence was low by CINeMA. Conclusion(s): Myval showed a favourable safety and procedural profile compared with contemporary THVs. It had lower permanent pacemaker implantation rates than Portico and Allegra, while maintaining comparable short- and intermediate-term clinical outcomes. Although some supra-annular valves showed lower mean aortic valve gradients, Myval was associated with favorable conduction outcomes while maintaining acceptable haemodynamic performance. Further adequately powered head-to-head randomized controlled trials are needed to confirm these findings.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.